Ash Biomedical Diagnostics Ltd., a Nigerian firm, has announced the production of seven of its own-brand diagnostic medicines to manage and treat HIV, malaria, hepatitis, and pregnancy. The seven products include ABD HIVChek, MalChek, MalChek Plus, HepaQuik, HepaQuik Duo, PregSure, and FlaviQuik. These products comprise 12 Stock Keeping Units (SKUs) covering four critical healthcare testing areas.
The Managing Director of Ash Biomedical, Adetoyese Shodeinde, stated that the achievement reflected years of deliberate investment in quality, regulatory compliance, and product development. Shodeinde explained that among the newest additions now available nationwide were FlaviQuik, designed for Hepatitis C rapid testing, and HepaQuik Duo, which enables dual screening for Hepatitis B and Hepatitis C using one test.
Shodeinde stressed that for Nigerians, the significance of the milestone extended beyond product availability, adding that it represents continued progress towards strengthening confidence in locally developed healthcare solutions while expanding access to rapid diagnostics capable of supporting earlier disease detection. He emphasized that NAFDAC registration provided the formal regulatory basis for the products to be marketed in Nigeria.
Shodeinde said that Ash Biomedical’s vision has always been bigger than producing diagnostic kits. The company aims to build confidence in Nigerian healthcare manufacturing by ensuring that every product carrying the Ash Biomedical name meets the standards required for quality, reliability, and national regulatory approval.
Ash Biomedical’s expanded hepatitis portfolio arrived as increased hepatitis screening continued to draw national and global attention. The managing director said through FlaviQuik and HepaQuik Duo, Ash Biomedical was contributing additional rapid diagnostic options that supported healthcare professionals in screening patients more efficiently.
Founded in 2011, Ash Biomedical has steadily grown from a Nigerian diagnostics company into a recognised manufacturer with products reaching healthcare institutions across the federation. The company has delivered 15 million test kits over 15 years through more than 66 government and institutional contracts across 27 states.
Independent hospital evaluations found 100 per cent concordance between Ash Biomedical rapid-test results and reference laboratory findings across HIV, hepatitis B, pregnancy, and malaria testing in the evaluated samples. These achievements provided important evidence that local manufacturing and quality are possible in Nigeria.
Key points
- Ash Biomedical produces seven diagnostic medicines for HIV, malaria, hepatitis, and pregnancy.
- The company has delivered 15 million test kits over 15 years through government and institutional contracts.
- Ash Biomedical’s products have reached all 36 states of Nigeria.
